Introduction
============

The publication of the first sequence of the human genome is regarded as one of the major landmarks in modern biological research. The Human Genome Project represented the collective efforts of scientists in many countries, funded through public programs and private enterprise. The first sequence took 13 years to accomplish;[@b1-rmhp-8-009] not much more than a decade later, next generation sequencing (NGS) technologies -- including whole genome or exome sequencing (WGS/WES) -- are becoming increasingly available in many hospital laboratories, with a number of published case studies in North America and Europe.[@b2-rmhp-8-009]--[@b8-rmhp-8-009] The "\$1,000 genome" is more or less here.[@b1-rmhp-8-009] Major public bodies are currently supporting exploratory initiatives which integrate NGS into aspects of routine clinical care. For example, in the US, the National Institutes of Health have funded three projects examining the use of NGS as part of established newborn screening programs;[@b9-rmhp-8-009] and, in the UK, a major publicly-funded initiative aims to sequence the genomes of 100,000 patients, with a view to learning "new medical insights" and "bring benefits to patients".[@b10-rmhp-8-009]

These technological advances have been accompanied by claims that we are on the cusp of a paradigm shift to an age of personalized medicine that "... uses an individual's genetic profile to guide decisions made in regard to prevention, diagnosis, and treatment of disease."[@b11-rmhp-8-009] This is a profound shift in thinking from genetics as a specialist interest addressing rare disorders to the use of genetic information in all aspects of health care. The purpose of this review is to discuss proposals for using genomic approaches in population screening contexts, to describe the current challenges and evidence gaps, and to suggest priorities for public policy and practice.

From clinical genetics to personalized medicine
-----------------------------------------------

The focus of traditional clinical genetics has been on identifying monogenic disorders, often pre-specified on the basis of a person's family history, ethnicity, or medical history. These variants -- mutations -- are usually of high penetrance, ie, carrying the mutation is associated with a high likelihood of developing the disorder in question. The family history may point to dominant, recessive, X-linked, or some other form of single gene (monogenic), Mendelian inheritance.

In terms of service organization and culture, medical genetics departments are generally specialist units, often located in tertiary care facilities, sometimes linked with dedicated testing laboratories, and staffed by medical genetics specialists and formally trained genetic counselors. Patients are usually referred on the basis of an unusual family history, birth of a child with a serious congenital anomaly, or diagnosis of a suspected genetic condition. Genetic assessment is a painstaking process, of which comprehensive family history collection is a central activity. Genetic counseling also includes assessment of patients' information and emotional needs, and -- because the balance of benefits and harms is highly individualized -- is usually non-directive.

In contrast, personalized medicine is conceived as more broadly applicable across health care. It includes the strategy of genetic profiling to offer individual risk information for multifactorial disorders (eg, cardiovascular disease,[@b12-rmhp-8-009] cancers,[@b13-rmhp-8-009] and type 2 diabetes[@b14-rmhp-8-009]), where disease risk results from interaction between several genes (polygenic) as well as non-genomic factors. Genetic profiling often involves measuring single nucleotide polymorphisms (SNPs): variations in the smallest building blocks of DNA.[@b15-rmhp-8-009] While SNPs may lead to mutations that cause monogenic disorders (which are generally rare, usually sufficient in themselves to cause disease, and are more readily identifiable as causative),[@b16-rmhp-8-009] SNPs associated with more common, complex diseases, generally convey only minor excess risk[@b17-rmhp-8-009] making them more difficult to identify when embedded within a background of widespread non-pathogenic variation across the genome.[@b16-rmhp-8-009]

Genetic profiling may be narrowly targeted, using defined panels of SNPs designed to provide risk information for a specific health condition (eg, colorectal cancer), or may be less targeted, with SNP-based genome-wide profiling addressing multiple disorders.[@b18-rmhp-8-009] Least targeted are those approaches that use NGS technologies to provide "complete" genomic information on an individual.[@b19-rmhp-8-009] Thus, the scope of "personalized medicine" may range from targeted testing of one or several mutations associated with rare monogenic, high penetrance disorders at one extreme to, at the other, sequencing a patient's exome or genome without targeting specific variants.

Ultimately, the service model underpinning the delivery of personalized medicine is that of "genomics in medicine" -- the integration of genomic testing with other clinical investigations, delivered by health care professionals who are not medical geneticists, and where a positive test result does not imply a serious genetic diagnosis, rather is interpreted alongside the entirety of a patient's health and medical data.

Prospects for population screening
==================================

Screening is the "systematic, proactive offer \[of a test\] to members of a certain group of individuals".[@b20-rmhp-8-009] This differs distinctly from clinical genetics in that the application of the screening test is not initially pre-specified on the basis of a person's family or medical history. The goal of screening is disease detection at an early or precursor phase, where intervention may alter natural history. The orientation of personalized medicine approaches to identifying individual disease susceptibility has opened up discussion of the possible benefits of using genomic information to improve existing population screening programs.[@b20-rmhp-8-009]--[@b24-rmhp-8-009]

Genetic information already forms the basis for many screening tests applied to asymptomatic individuals, using direct DNA-based methods or phenotypic markers (eg, biochemical) of genetic or chromosomal conditions ([Table 1](#t1-rmhp-8-009){ref-type="table"}). These fit largely within the model of traditional genetics services, and some genetic screening programs have been available for over 30 years. Examples include antenatal screening for major chromosomal anomalies,[@b25-rmhp-8-009] newborn screening for serious genetic disorders,[@b26-rmhp-8-009],[@b27-rmhp-8-009] family-based cascade screening of first and second degree relatives of individuals diagnosed with genetic conditions,[@b20-rmhp-8-009],[@b25-rmhp-8-009],[@b28-rmhp-8-009] and carrier screening of targeted population groups to inform reproductive planning or early disease detection.[@b27-rmhp-8-009],[@b29-rmhp-8-009]

New strategies for identifying sub-groups of patients with monogenic versions of common serious disorders are being evaluated, blurring the boundary between diagnostic investigation and targeted screening. For example, while it is currently not feasible to test all breast cancer patients for genetic susceptibility (although this has recently been proposed),[@b30-rmhp-8-009] specific tumor phenotypes (eg, receptor status) may provide a clue to genetic etiology, and prompt germline mutation testing in the patient.[@b31-rmhp-8-009] A positive *BRCA1/2* test would do more than explain an existing diagnosis: the patient would be at risk of a second breast cancer, malignancies in other organs, and might benefit from altered management and surveillance. The result would also alert clinicians to the importance of offering at-risk relatives genetic counseling and mutation testing, if appropriate.

For reasons of space, we do not discuss further these approaches described above. Neither do we discuss family history as a form of personalized medicine (we direct readers toward other reviews which cover this topic comprehensively),[@b32-rmhp-8-009],[@b33-rmhp-8-009] nor developments in direct to consumer availability of genetic tests (a complex topic that merits an article in its own right).[@b34-rmhp-8-009]--[@b37-rmhp-8-009] The main focus of this article is on emerging prospects for personalizing screening, specifically two general approaches that illustrate recent thinking about how genetic information may be used in screening. The first is a narrowly targeted approach in which genetic profiling is linked with standard population-based screening for single disorders; the second is broader assessment of variants associated with multiple single gene disorders, performed opportunistically on patients being investigated for unrelated conditions.

Personalized screening
----------------------

Population screening involves the offer of a test to a target population, for the purpose of disease (or pre-disease) detection at a sufficiently early stage for interventions to reduce mortality and/or morbidity. The principle of risk stratification is already universally embedded in population screening approaches, in the form of age-based eligibility criteria. Age is an easily applied individual attribute, and is a way of operationalizing a risk threshold where screening is considered worthwhile, because of a favorable balance of harms, benefits, and cost to society. For example, the risk threshold used by the UK National Breast Screening Programme is a 10 year absolute risk of ≥2.5%; this translates to age eligibility of 47--73 years.[@b22-rmhp-8-009] However, even honing down on a population group exceeding an age-based risk threshold, it is inevitable that all population-based screening programs experience an unavoidable rate of false positive and false negative screen results.

A number of groups have explored the use of targeted genetic profiling as a way of increasing the accuracy of risk stratification. Setting aside the rare monogenic forms of usually complex disorders, individual genetic variants generally confer only a small increase in individual disease risk, and even panels with multiple variants are poor at discriminating disease risk in individuals.[@b38-rmhp-8-009] However, when combined with age, genetic panels may offer more accurate risk stratification and indicate more tailored approaches to the timing or intensity of screening tests (so-called "personalized screening"). For example, for individuals in a highest risk stratum, surveillance might begin at a younger age or screening frequency shortened; while individuals in lower risk strata might benefit from a reduction in screening intensity.

Pashayan et al[@b39-rmhp-8-009] model this approach using the UK National Breast Screening Programme as a case study. They use as an example a panel of 67 common SNPs that explain approximately 14% of the genetic component of breast cancer risk. They calculate that profiling using this panel plus age would lead to some women as young as 35, and some as old as 79, being offered screening because they reach the threshold of 2.5% 10 year absolute risk; conversely, 24% fewer women aged 47--73 would be reclassified below the risk threshold and therefore not offered screening.[@b39-rmhp-8-009] Overall, 3% fewer cases would be detected (lower sensitivity), but there would be a lower rate of false positive screens (higher specificity). If this group's analyses are valid, the addition of targeted genetic profiling would potentially lead to some missed cancers, a reduction in unnecessary diagnostic investigations, a higher detection rate of (predicted to be more aggressive)[@b40-rmhp-8-009] cancers in younger individuals, and reduction in over-diagnosis of indolent or latent cancers. Similar arguments have been proposed for screening for colorectal cancer[@b41-rmhp-8-009],[@b42-rmhp-8-009] and prostate cancer.[@b39-rmhp-8-009]

Genetic profiling for stratification of population-based screening must be formally evaluated.[@b24-rmhp-8-009],[@b39-rmhp-8-009],[@b43-rmhp-8-009],[@b44-rmhp-8-009] Predictions about risk reclassification, disease detection, and changing eligibility for screening need to be confirmed in empirical studies in representative populations, and randomized controlled trials comparing personalized screening with current approaches would allow quantification of benefits, harms, and costs in actual practice. While it is anticipated that personalized screening would reduce negative psychosocial impacts of screening, there are multiple issues which would need to be taken into account (discussed below) before genetic profiling could be considered for widespread implementation.

Opportunistic screening as part of WGS/WES
------------------------------------------

The second emerging pattern for genome-based screening is linked to the increasing application of NGS technologies (sequencing and associated bioinformatics capabilities) as clinical tools. This has become possible as their costs fall and their application in clinical settings has been boosted by major research funding, particularly in the US.[@b45-rmhp-8-009] The earliest areas of clinical exploration and application have been in the investigation of rare disorders which elude standard genetic diagnostic approaches, the individualization of cancer treatment,[@b46-rmhp-8-009] and prenatal/preconception screening and preventive health assessment.[@b47-rmhp-8-009],[@b48-rmhp-8-009] Having sequenced an individual's entire genome or exome during the course of clinical investigation, it is a short step to interrogating it for variants with known or suspected pathogenic potential as a form of opportunistic screening, unrelated to the original clinical indication. This screening approach has been most notably supported by the American College of Medical Genetics and Genomics; this professional body published recommendations which listed 57 genetic variants related to 24 conditions that should be reported for every patient undergoing WGS/WES.[@b49-rmhp-8-009] The recommendations refer to these variants as "incidental", and define them as "the results of a deliberate search for pathogenic or likely pathogenic alterations in genes that are not apparently relevant to a diagnostic indication for which the sequencing test was ordered".[@b49-rmhp-8-009] The variants are generally associated with rare single gene disorders, and were selected by expert consensus as representing conditions which are "clinically actionable", ie, for which confirmatory diagnostic approaches are usually available; where preventive or treatment interventions are usually available; and where there is usually a long pre-symptomatic period. Examples include genes associated with hereditary breast and ovarian cancer, retinoblastoma, neurofibromatosis, and several cardiomyopathies (for a full list, please refer to Green et al[@b49-rmhp-8-009]). The recommendations suggest that only around 1% of sequencing reports would be expected to include incidental variant information,[@b50-rmhp-8-009] and the clinician ordering the sequencing for the initial indication would be responsible for interpreting the significance of results in the light of the patient's complete clinical information, disclosing the findings appropriately, and advising patients on appropriate clinical management.[@b26-rmhp-8-009],[@b51-rmhp-8-009]

While these recommendations will inevitably evolve as knowledge accumulates, the underlying approach of opportunistic screening to find undiagnosed cases is one familiar to public health practice. The proponents for this targeted genetic screening approach point to benefits in disease prevention, prompt treatment, informed reproductive planning, and cascade testing of at-risk relatives.[@b49-rmhp-8-009] However, the recommendations have attracted considerable criticism that the evidence base is lacking for many of the assumptions, particularly the possibilities for false positives.[@b52-rmhp-8-009] Some of the challenges are discussed below.

Challenges to genomic approaches to screening
=============================================

Inadequate evidence base
------------------------

Many observers assert that, to date, there is inadequate empirical evidence available to support informed policy decisions about the use of genetic profiling in personalized screening, or of opportunistic screening as part of WGS/WES. The most helpful evidence for policy making relates to effectiveness in practice, compared with standard of care (also referred to as "clinical utility").[@b53-rmhp-8-009] The overall utility of a genetic approach to screening depends on how processes of care are altered, such as alteration in personal or clinical decision making, and the effectiveness of preventive or therapeutic interventions which flow from these decisions. The ultimate test of clinical utility is the impact on patient health outcomes, including changes in morbidity and mortality of the target condition, and also positive and negative psychosocial outcomes such as changes in personal risk perception, emotional impacts of risk information, and benefits from minimizing diagnostic delay, etc.[@b53-rmhp-8-009],[@b54-rmhp-8-009] Randomized controlled trials, and decision analytic modeling, addressing the range of relevant outcomes and incorporating the effect of downstream interventions form the core approaches to estimating clinical utility.[@b55-rmhp-8-009]

However, in relation to personalized screening and opportunistic screening allied with NGS, the major evidence challenges at present relate to analytic and clinical validity ([Table 2](#t2-rmhp-8-009){ref-type="table"}). Analytic validity refers to the technical performance of a test:[@b56-rmhp-8-009] how accurately and reliably the laboratory assay measures the variant in question. The primary metrics are analytic sensitivity -- a positive test result when the variant in question is known to be present -- and analytic specificity -- a negative test result when the variant is known to be absent,[@b18-rmhp-8-009],[@b56-rmhp-8-009] but also includes evaluations of assay robustness and laboratory quality control.[@b20-rmhp-8-009] For personalized screening, confidence in a negative result is dependent on the completeness of the variants included in a panel in relation to the target population.[@b57-rmhp-8-009] Panels with an inadequate number of variants will have low sensitivity, with the possibility of erroneous re-classification of some individuals to lower risk strata.[@b58-rmhp-8-009]

For opportunistic screening performed as part of NGS, analytic validity depends on the "depth of read" provided by sequencing platforms; that is how many times a nucleotide is read during the sequencing process. Higher read depth will provide greater coverage, but higher costs. Lower coverage may decrease costs but may provide only lower confidence in the observed variants. As such, there is a compromise with respect to cost-effectiveness of different depths of read. Early work indicates considerable variation in genotype accuracy depending on the specific technique used.[@b59-rmhp-8-009] One study which focused specifically on the American College of Medical Genetics and Genomics' recommendations noted that two different sequencing platforms failed to cover 9%--17% of the listed variants.[@b60-rmhp-8-009],[@b61-rmhp-8-009] This suggests the possibility for false negatives, leading to difficulties in interpreting the meaning of "normal" screening results.

In the context of genetics, clinical validity refers to the ability of a test to accurately predict the trait or condition in question, or stratify future disease risk or prognosis. In personalized medicine, this must be considered in comparison with standard non-genomic approaches such as routine biochemical tests, clinical or physical measurements, etc. The metrics of clinical validity are also those of test evaluation (sensitivity, specificity, positive and negative predictive value, and area under the receiver-operator characteristics curve), and meaningful evaluation must take account of the target population and comparison with standard (non-genetic) risk prediction models.[@b24-rmhp-8-009],[@b56-rmhp-8-009]

For personalized screening, the first evidence challenge is in selecting, from the considerable literature on gene-disease associations, those variants for which the association has been validated, and which offer useful independent information when incorporated into a screening panel. Initial evaluations that suggested that only a few variants might be necessary to explain a large proportion of the population risk for a complex disorder appear to be over-optimistic.[@b62-rmhp-8-009]--[@b64-rmhp-8-009] We have offered the example of a panel with 67 variants for breast cancer risk above; for colorectal cancer, some authors have estimated that in excess of 100 variants would be required to achieve acceptable classification accuracy.[@b65-rmhp-8-009] Initiatives such as the Evaluation of Genomic Applications in Practice and Prevention group have reviewed gene panels for conditions such as cardiovascular disease, type 2 diabetes, and ovarian cancer[@b56-rmhp-8-009],[@b66-rmhp-8-009]--[@b68-rmhp-8-009] and concluded insufficient evidence to make recommendations for clinical application. This work has been continued by the US Centers for Disease Control, which maintains a list of genomic tests grouped by evidence supporting their use.[@b69-rmhp-8-009],[@b70-rmhp-8-009]

For opportunistic screening associated with NGS, the concern is one of interpretability: what is the evidence that a presumed pathogenic mutation will cause significant disease in the person's lifetime? Several studies have suggested that up to two thirds of so-called disease-causing mutations found within the Human Gene Mutation Database[@b71-rmhp-8-009],[@b72-rmhp-8-009] may be misclassified and carry lower or no clinically meaningful pathogenicity.[@b61-rmhp-8-009],[@b73-rmhp-8-009],[@b74-rmhp-8-009] Work is needed to curate and validate existing data on identified mutations in order to better characterize them, especially those classed as "variants of unknown significance".[@b58-rmhp-8-009] In addition, our understanding of the natural history of risk associated with many apparently well understood variants is increasingly challenged. It may be possible to extrapolate from experience with expanded newborn screening panels. As many (genetic) inborn errors of metabolism are now detected through biochemical screening in the neonatal period instead of through clinical symptoms presenting in later infancy or childhood, the apparent prevalence for some conditions appears to have risen.[@b75-rmhp-8-009],[@b76-rmhp-8-009] It is becoming evident that some "pathogenic" genotypes may actually be associated with a wider range of phenotypes, including asymptomatic and milder forms of disease.[@b76-rmhp-8-009] There is concern about over-diagnosis and overtreatment of some individuals resulting from the "genetic diagnosis" of a condition which would never have manifested over the course of a lifetime.[@b25-rmhp-8-009]

The potential application of NGS to produce extensive genomic assessments in asymptomatic populations has the potential "to yield unexpected incidental findings for nearly everyone".[@b77-rmhp-8-009] This has been coined "the incidentalome"[@b77-rmhp-8-009] and it has been estimated that a genome screen of an average patient would generate hundreds of false positive genetic test results.[@b78-rmhp-8-009] It should be remembered that, because the context is risk assessment, there is no gold standard at the point of testing against which to judge screening test performance.[@b79-rmhp-8-009]

Ethical, legal, and social issues
---------------------------------

### Privacy and third-party access

A concern within some existing screening programs, and which may be enhanced by the inclusion of personal genomic testing as part of population screening, relates to the privacy afforded to collected samples.

This issue has been widely highlighted in relation to newborn screening programs, in which samples retained for quality assurance and diagnostic purposes may also -- in some jurisdictions -- be made available for research.[@b80-rmhp-8-009] Such research may include clinical studies to advance knowledge regarding particular conditions -- bloodspots have been used to identify if mutations associated with childhood leukemia are congenital or accumulate over time -- but also for public health research such as the effect of public health policies in reducing exposure to environmental pollutants.[@b81-rmhp-8-009] It has also been proposed that bloodspots could be used for forensic purposes.[@b82-rmhp-8-009],[@b83-rmhp-8-009] Such policies have, however, raised concerns over privacy and who should have access to samples collected -- at least initially -- for clinical purposes, and has motivated discussion regarding the extent to which consent given in a population screening context may cover activities beyond the primary purpose.[@b82-rmhp-8-009],[@b84-rmhp-8-009],[@b85-rmhp-8-009] Lawsuits in the US and Canada[@b86-rmhp-8-009],[@b87-rmhp-8-009] challenging such secondary uses of biological material obtained through screening have led to changes in storage policy and, in some cases, the destruction of millions of stored samples.[@b86-rmhp-8-009] The incorporation of genomic testing within other population screening programs would likely face similar issues pertaining to initial consent for screening, but also sample retention and secondary use.

Discussions about genetics are also, almost inevitably, accompanied by concerns about implications for individual insurance eligibility. While practice varies internationally, some jurisdictions have enacted legislation in an attempt to address concerns. In the US the 2008 Genetic Information Nondiscrimination Act prohibits group health plans and health insurers denying coverage or charging higher premiums to healthy individuals based solely on genetic test results. Several other countries, such as the UK, have also taken steps to limit the use of genetic test information for the purposes of life insurance underwriting.[@b88-rmhp-8-009]--[@b90-rmhp-8-009] The use of NGS in identifying incidental variants parallels traditional genetic testing, and it would be expected that patients discovering risk of serious conditions this way would face similar experiences to patients managed in traditional clinical genetics clinics.

It might be expected that similar issues would be faced by individuals receiving genomic information, irrespective of whether this is in the course of general medical care or traditional genetic testing. However, the complexity of interpreting the genomic contribution to the risk of complex disorders[@b60-rmhp-8-009] raises important empirical questions over whether such information can be used accurately for insurance underwriting purposes. Other concerns are more philosophical: they turn on questions of whether life or health insurance is seen as an essential social good,[@b91-rmhp-8-009]--[@b93-rmhp-8-009] and so whether there should be universal access to insurance irrespective of prior or predicted health risks.[@b94-rmhp-8-009],[@b95-rmhp-8-009]

To date, the empirical data regarding genetic testing and insurance discrimination suggest that concerns have been overstated.[@b20-rmhp-8-009] In Canada, a recent policy brief noted that the empirical evidence is equivocal regarding the levels of reported genetic discrimination, and it is unclear whether reported cases of discrimination could be attributed to genetic testing per se or to family history. Moreover, it noted a lack of clarity whether reported cases represented perceived as distinct to actual discrimination. A 2013 systematic review on this topic concluded that, while there may be individual cases of genetic discrimination, existing research was not sufficiently robust to establish the prevalence or impact of discriminatory practices.[@b96-rmhp-8-009]

As for personalized (stratified) screening, it might be argued that more accurate risk assessment would have no net effect at a population level, and might in fact produce net avoidance of insurance concerns if more individuals were correctly classified as lower risk than occurs with standard age-based approaches.

### Psychosocial effects

There is an extensive literature on psychosocial aspects related to disclosing personal genetic risk to individuals, conducted mostly in the context of traditional clinical genetics,[@b97-rmhp-8-009]--[@b99-rmhp-8-009] with exploration of the impact of NGS technologies still at an early phase.

The evidence consistently suggests that genetic testing accompanied by pre-test genetic counseling is not associated with excess psychosocial risks in general, but some individuals do experience unduly high levels of adverse psychosocial outcomes.[@b99-rmhp-8-009] Systematic reviews have concluded that the individuals most at risk of psychological morbidity are those with higher pre-test levels of anxiety or depression.[@b98-rmhp-8-009] It is plausible that the low rate of psychological morbidity associated with genetic testing is due to some extent to the role played by genetic counselors in identifying patients for whom genetic testing may cause undue harm, and helping such individuals make informed decisions to decline testing. If so, there may be concerns about harms created by offering genetic profiling as part of regular population screening without specialist genetic counseling, or seeking out additional, unexpected genetic risks in patients consenting to WGS/WES (presumably for a serious medical situation). The earliest emerging studies in the era of NGS are in the field of direct-to-consumer genetic testing, in which consumers seek out personal genetic information, often from curiosity as much as any health concern.[@b36-rmhp-8-009],[@b100-rmhp-8-009],[@b101-rmhp-8-009] While such studies provide only indirect evidence relevant to the present discussion, they appear to indicate no evidence of excess post-test distress or anxiety.[@b102-rmhp-8-009]

Conversely, it has also been argued that knowledge of personal health risks arising from genetic predisposition can act as a motivator for positive behavior change.[@b103-rmhp-8-009] The evidence from studies conducted in individuals receiving standard clinical genetic testing tends to refute this.[@b97-rmhp-8-009],[@b104-rmhp-8-009],[@b105-rmhp-8-009] It is unclear whether these findings can be extrapolated to personalized screening approaches, and it has been argued that those who actively seek out personal risk information (eg, by buying direct-to-consumer test kits) may in fact be more likely than the general population to take action as a result. This area of enquiry is in its infancy, but the few studies available do not yet provide evidence to support this argument.[@b102-rmhp-8-009],[@b106-rmhp-8-009]

Implications for policy
=======================

Need for policy oriented research
---------------------------------

The tremendous enthusiasm for the "genetics revolution" in health care[@b107-rmhp-8-009] risks driving the dissemination of genetic approaches into practice without evidence of clinical validity or usefulness. The extensive reporting of genomic discovery research massively overshadows the small published literature directed toward application in practice. Evidence-based policy requires evaluations of clinical validity and utility of emerging applications; implementation research to support the integration of potentially useful applications into practice; and studies of the actual impact of genomic applications on health outcomes and impact on health systems.[@b108-rmhp-8-009] Interrogating the "HuGE Navigator"[@b109-rmhp-8-009] (a continuously updated knowledge resource on human genome research) for studies published between 2009 and 2013, it appears that only around 1% of articles address these policy-oriented questions (see <http://64.29.163.162:8080/HuGENavigator/home.do>). Over this 5- year period, more than 49,000 scientific articles on human genomics were published, of which only 519 were clinical trials, and 52 were reviews designed to inform clinical policy. Studies of gene discovery or gene-disease association are the foundation for developing novel genome-based tests but offer no evidence to clarify validity or utility in actual health care settings.

Role of public health
---------------------

Public health experts are well placed to apply standard evaluation frameworks, including the World Health Organization (WHO) criteria for screening,[@b110-rmhp-8-009] to emerging genetic screening tests, and to encourage research on clinical and public health utility, and economic evaluations.[@b20-rmhp-8-009] The WHO criteria remain applicable even when the test is genome based[@b27-rmhp-8-009] ([Table 3](#t3-rmhp-8-009){ref-type="table"}), although further complexities need to be taken into account such as concern about insurance or employment screening, and the possibility that lowering age thresholds because of genetic risk may lead to consideration of screening minors.[@b24-rmhp-8-009]

However, engaging the public health profession in reviewing and evaluating genomic screening applications may require a change in culture. Some public health practitioners may disregard genetics as not only irrelevant to population-based screening programs, indeed as quite opposite in philosophy.[@b20-rmhp-8-009] Although the evidence base is currently inadequate to support the widespread implementation of genetic approaches to screening, the work of several groups suggests that this cannot be discounted as a possible future direction.[@b111-rmhp-8-009]--[@b113-rmhp-8-009] Public health professionals are trained to take a population perspective, and to take an evidence-based approach to considering new health interventions. If emerging genetic applications are mistakenly discounted as irrelevant in the population perspective, there is a risk of delaying the development, evaluation, and practical implementation of potentially beneficial approaches which could make a meaningful impact on population health.

Organization of services
------------------------

Until relatively recently, in almost all health systems, genetic tests could be ordered only by geneticists, or selected specialists such as oncologists managing patients with familial cancer syndromes. This gatekeeping role is increasingly challenged as selected genetic tests are incrementally incorporated into laboratory requisition forms for use by specialists and primary care physicians. The potential inclusion of personal genomics within population screening will likely challenge this gatekeeping role further.

As genetics becomes integrated into mainstream medicine, as genetic tests are used in screening in "general" populations, and as testing becomes less targeted, it is inevitable that physicians will not always find it straightforward to interpret individual genomic test results. Close cooperation between primary care and specialist services may need to be intensified, but the model of genetic counseling as a requirement before testing[@b20-rmhp-8-009],[@b24-rmhp-8-009] would be unsustainable for incorporation into population screening programs.

Professional education
----------------------

Most studies indicate that, irrespective of who orders a genetic test in the first place, patients look to primary care physicians to offer advice and be ready to use genetic information in their care.[@b111-rmhp-8-009],[@b114-rmhp-8-009],[@b115-rmhp-8-009] Many studies have shown that primary care health professionals are positively disposed toward using genomics applications in their routine practice, and agree that counseling patients about health and disease risks is consistent with their continuing care role.[@b114-rmhp-8-009],[@b116-rmhp-8-009]--[@b122-rmhp-8-009] Although personal genomics should be well-suited to integration in discussions of health risks,[@b115-rmhp-8-009] many studies indicate that practitioners tend to lack confidence in their knowledge and skills, and seek practical interventions to support their efforts.[@b119-rmhp-8-009],[@b123-rmhp-8-009],[@b124-rmhp-8-009] The last two decades have seen a shift in educational approaches away from a simple "knowledge deficit" approach to targeting specialty-specific genetic competencies.[@b117-rmhp-8-009],[@b125-rmhp-8-009],[@b126-rmhp-8-009] This has matched the development of more multifaceted and sophisticated approaches to support the use of genetics which address the complexities of real life practice.[@b114-rmhp-8-009],[@b127-rmhp-8-009],[@b128-rmhp-8-009]

Informed decision making
------------------------

Surveys repeatedly suggest that members of the general population are interested in genetics[@b129-rmhp-8-009]--[@b132-rmhp-8-009] and would consider genetic testing for themselves and family members.[@b129-rmhp-8-009],[@b133-rmhp-8-009]--[@b137-rmhp-8-009] However, genuinely informed decision making about seeking or allowing genetic information in systematic or opportunistic screening demands a deeper appreciation of personal implications, including the possibility of receiving results which have unclear health significance; individuals need to be prepared for unexpected impact on their emotional state, family issues, access of (potential) employers and insurance companies to risk information, etc. In a clinical context, informed decision making can be supported by evidence-based decision aids[@b138-rmhp-8-009] and by providers who themselves are confident in their own understanding of genetics. However, if and when genetically-based risk stratification becomes more widespread, there is no guarantee that such a personal clinical model will apply. A thoughtful approach to public educational needs to support general literacy about genomics in health care would be desirable as a foundation for well-informed use of genetic information in population health, health care, and non-medical aspects of life.[@b128-rmhp-8-009]

Conclusion
==========

Personalized medicine and personal genomics have been described as paradigm-shifting technologies in medicine,[@b139-rmhp-8-009] although their pace of implementation may perhaps be better described as a slow revolution in health care. There are significant challenges in moving from traditional genetics, with its focus on monogenic disorders with significant implications for health of a very small proportion of the population, to the development of genetic profiling approaches which are useful for screening, risk assessment, disease prevention, and health promotion. The idea of personalized medicine as fully individualized medicine has still to be realized, and is likely unrealistic.[@b140-rmhp-8-009] However, the application of genetics in stratifying screening approaches, with potential for real health benefit (and better use of health care resources) is realistic and perhaps in reach within the next few years.

All new technologies are propelled into practice by their champions and enthusiasts, and the drivers behind personalized medicine include major funding bodies, large health care organizations, and even national governments. However, careful evaluation of health benefits achievable in practice, acknowledgment of the need to identify and quantify potential harms, and the economic implications are as important in personalized medicine as any other area of health care. It is particularly important that public health experts themselves embrace their role in this, and engage positively in framing the research agenda from a population perspective.

In addition the assessments of technologies, approaches to public and professional education will need to be developed. These will need to support general literacy about genomics in health care and should be a foundation for the well-informed use of genetic information in population health, and health care more generally.
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###### 

Genetic screening interventions

  Screening intervention                          Target population                                                                         Example conditions
  ----------------------------------------------- ----------------------------------------------------------------------------------------- -----------------------------------------------------------------------------
  **Currently available**                                                                                                                   
  Pre-conceptional screening                      Individuals planning pregnancy                                                            Recessive conditions, eg, cystic fibrosis
  Antenatal screening                             Pregnant individuals                                                                      Major chromosomal anomalies, eg, Down syndrome
  Newborn screening                               Neonates                                                                                  Inborn errors of metabolism, eg, phenylketonuria
  Cascade screening                               First and second degree relatives of individual with genetic disorder                     Recessive conditions, eg, familial hypercholesterolemia
  Population carrier screening                    Defined population subgroups                                                              Genetic conditions with high prevalence in subgroup, eg, hemoglobinopathies
  Direct-to-consumer tests                        Individuals willing to purchase                                                           Common disease susceptibility, eg, cardiovascular disease
  **Potential/in development**                                                                                                              
  Disease-based case finding                      Patients with common serious conditions                                                   Common conditions with genetic subtypes, eg, some cancers
  Personalized/stratified population screening    Target population for standard (non-genetic) screening                                    Conditions screened for at population level, eg, colorectal cancer
  Case finding in whole genome/exome sequencing   Patients undergoing whole genome/exome sequencing for clinical diagnostic investigation   Rare "actionable" genetic mutations, eg, retinoblastoma

###### 

Framework for evaluating genetic tests

  -------------------------------------------------------------------------------------------------------------------------------------------------------
  Components and definitions                                             Measures
  ---------------------------------------------------------------------- --------------------------------------------------------------------------------
  **Analytic validity**\                                                 Analytic sensitivity and specificity\
  Ability to accurately and reliably measure genotype of interest        Laboratory quality control\
                                                                         Assay robustness

  **Clinical validity**\                                                 Clinical sensitivity and specificity\
  Ability to detect or predict disorder of interest                      Prevalence of disorder\
                                                                         Test positive and negative predictive value\
                                                                         Penetrance\
                                                                         Modifiers

  **Clinical utility**\                                                  Natural history of condition\
  Risks and benefits when used in routine practice                       Availability and effectiveness of treatment or preventive interventions\
                                                                         Education\
                                                                         Economic evaluation\
                                                                         Monitoring and evaluation

  **Ethical, legal, and social issues**\                                 Stigmatization, discrimination, privacy/confidentiality, family/social issues\
  Cross-cutting factors which infuence all aspects of test in practice   Consent, ownership of data/samples, licensing, patents\
                                                                         Safeguards and effectiveness
  -------------------------------------------------------------------------------------------------------------------------------------------------------

**Note:** Data from.[@b57-rmhp-8-009]

###### 

Principles of population screening as applied to genetic susceptibility to disease

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Public health assessment**

  The disease or condition should be an important public health burden to the target population in terms of illness, disability, and death.\
  The prevalence of the genetic trait in the target population and the burden of disease attributable to it should be known.\
  The natural history of the condition, from susceptibility to latent disease to overt disease, should be adequately understood.

  **Evaluation of tests and interventions**

  Data should be available on the positive and negative predictive values of test with respect to a disease or condition in the target population.\
  The safety and effectiveness of the test and accompanying interventions should be established.

  **Policy development and screening implementation**

  Consensus regarding the appropriateness of screening and interventions for people with positive and negative test results should be based on scientific evidence.

  Screening should be acceptable to the target population.\
  Facilities should be available for adequate surveillance, prevention, treatment, education, counseling, and social support.\
  Screening should be a continual process, including pilot programs, evaluation of laboratory quality and health services, evaluation of the effect of screening, and provisions for changes on the basis of new evidence.

  The cost effectiveness of screening should be established.\
  Screening and interventions should be accessible to the target population.

  There should be safeguards to ensure that informed consent is obtained and the privacy of those tested is respected, that there is no coercion or manipulation, and that those tested are protected against stigmatization and discrimination.
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Note:** From *N Engl J Med*. Khoury MJ, McCabe LL, McCabe ER. Population screening in the age of genomics medicine. 2003;348(1):50--58. Copyright © 2003 Massachusetts Medical Society. Reprinted with permission from Massachusetts Medical Society.
